Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UnitedHealth Part D exec to depart

Executive Summary

Lois Quam, executive VP and president of the Public and Social Markets Group, is leaving the company to join investment banking and securities firm Piper Jaffray. She will be succeeded at United by Anthony Welters, previously president, CEO and co-founder of AmeriChoice, an administrator of public sector health care programs acquired by United in 2002. Quam, who has been with United for 18 years, led the start up of the company's market-leading Medicare Part D program. Also leaving United is Richard Anderson, exec VP and president of the Commercial Services Group. He will be succeeded by William Munsell, previously CEO of the company's Specialized Care Services group and chief administrative officer, United Healthcare...

You may also be interested in...



Merck KGaA's Diversified Business Model Proves Its Worth During Pandemic

Germany’s Merck KGaA rapidly expanded its life sciences services business to support the manufacture of COVID-19 vaccines during 2020, and also expects cancer and multiple sclerosis products to fuel its sales growth in coming years.

UCB Aims To Tailor Myasthenia Gravis Therapy Options To Patients

Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.

EU Industry Decries Price Cuts And Clawbacks

A detailed report published by Medicines for Europe setting out policies affecting the off-patent industry across 22 European countries demonstrates the urgent need for pricing and reimbursement and procurement reforms, the association insists.

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel